Previous 10 | Next 10 |
Galapagos (NASDAQ: GLPG ): 9M GAAP EPS of €4.59. More news on: Galapagos NV, Earnings news and commentary, Healthcare stocks news, Read more ...
Deals and Financings Taimei Technology, a Shanghai-Jiaxing SAAS company, completed a $212 million Series E/E+ round to advance its cloud AI-based suite of clinical trial programs. The company says its platform enables clinical research collaboration between sponsors, sites, CROs, patients,...
HitGen has entered into a drug discovery research collaboration with Galapagos NV (NASDAQ: GLPG ) to identify potential small molecule leads against targets of interest to Galapagos NV. More news on: Galapagos NV, Healthcare stocks news, Read more ...
Gilead Sciences (NASDAQ: GILD ) and licensor Galapagos NV (NASDAQ: GLPG ) announce long-term results from Phase 3 clinical trials, FINCH 1 and FINCH 2 , evaluating JAK1 inhibitor filgotinib in patients with moderately-to-severely active rheumatoid arthritis (RA). More news on: Gi...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely activ...
My investment strategy consists of picking stocks with a strong management team, an important competitive advantage and possible high cash flow margins. Meanwhile I prefer not to take too much risk while investing. Normally, biotech companies should be avoided applying this strategy. In fact, ...
If you only looked at year-to-date performance, Galapagos (NASDAQ: GLPG) would be a slam-dunk pick over Vertex Pharmaceuticals (NASDAQ: VRTX) . Galapagos is up more than 70% so far this year, while Vertex has achieved only a single-digit percentage gain. But choosing a stock based on its...
Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
The FDA approves privately held Boehringer Ingelheim's Ofev (nintedanib) to slow the rate of decline in pulmonary function in adult patients with interstitial lung disease associated with systemic sclerosis , a rare disorder of unknown cause characterized by diffuse scarring and va...
Gilead Sciences ( GILD ) has had a rough past five years, judging by its stock price, which peaked back in 2015. However, throughout this period, cash generation has been strong and was used to make a major acquisition, Kite in 2017 and, recently, to make an investment and licensing deal with ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...